EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Impact of acid blocker therapy on growth, gut microbiome, and lung disease in young children with cystic fibrosis

Cathy Liu, Taiya R Bach, Philip M Farrell, Derek Pavelec, Nicholas J Antos, Michael J Rock, Fadi Asfour, Michelle Howenstine, Jonathan M Gaffin, HuiChuan J Lai

Journal of Pediatric Gastroenterology and Nutrition · 2024

DOI: 10.1002/jpn3.12389 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2024. Verfasst von Cathy Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Gastrointestinal Microbiome, Proton Pump Inhibitors, Histamine H2 Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CF Foundation, NIH HHS, University of Wisconsin School of Medicine and Public Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Acid blocker therapy (ABT) has become common in cystic fibrosis (CF), despite insufficient evidence for benefits and studies showing potentially negative effects. We examined associations between ABT usage and growth, gut microbiome (GM), and early‐onset lung disease in young children with CF.

Methods

One hundred and forty‐five infants with CF born during 2012–2017, diagnosed through newborn screening by age 3 months and followed to 36 months of age at six CF centers were evaluated. Longitudinal data on growth, pancreatic functional status, pulmonary symptoms, and acid blocker medications were prospectively collected. Early‐onset lung disease severity was evaluated by a clinical scoring system. GM composition was assessed by 16S rRNA methodology.

Results

ABT use before age 3 years was frequent, with 81 (56%) of patients on H2 receptor antagonist (H2RA) or proton pump inhibitor (PPI), and higher among pancreatic insufficient (60%) versus pancreatic sufficient (26%) children. H2RA was commonly prescribed in infancy before transitioning to PPI. Growth improvements were not significantly greater, while GM α‐diversity at 3 years of age was significantly lower and early‐onset lung disease more severe, in persistent ABT users compared to nonusers of ABT.

Conclusion

In our cohort of young children with CF, early and persistent ABT use was not associated with significant growth benefits and instead showed associations with reduced GM diversity and negative effects on early‐onset lung disease. Consequentially, there is a critical need for systematic evaluation and comprehensive risk–benefit analysis of ABT to ensure proper guidelines for children with CF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisGastrointestinal MicrobiomeProton Pump InhibitorsHistamine H2 AntagonistsHumansMaleInfantFemaleChild, PreschoolInfant, NewbornLung DiseasesProspective Studies

Stichwörter der Autor:innen

gastroesophgeal refluxmalnutritionpancreatic insufficiencyproton pump inhibitorspulmonary exacerbation

Substanzen

Proton Pump InhibitorsHistamine H2 Antagonists

Autor:innen und Institutionen

  • Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
  • Department of Nutritional Sciences, College of Agriculture and Life Sciences, University of Wisconsin, Madison, Wisconsin, USA.
  • Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
  • Bioinformatics Resource Center, UW Biotechnology Center, University of Wisconsin-Madison, Wisconsin, USA.
  • Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.

Förderung

  • CF Foundation
  • NIH HHS
  • University of Wisconsin School of Medicine and Public Health
  • NIDDK NIH HHS

Zitieren

APA

Liu, C., Bach, T. R., Farrell, P. M., Pavelec, D., Antos, N. J., Rock, M. J., Asfour, F., Howenstine, M., Gaffin, J. M., & Lai, H. J. (2024). Impact of acid blocker therapy on growth, gut microbiome, and lung disease in young children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.12389

Vancouver

Liu C, Bach TR, Farrell PM, Pavelec D, Antos NJ, Rock MJ, et al. Impact of acid blocker therapy on growth, gut microbiome, and lung disease in young children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition. 2024. doi:10.1002/jpn3.12389

BibTeX
@article{Liu2024,
  author = {Liu, Cathy and Bach, Taiya R and Farrell, Philip M and Pavelec, Derek and Antos, Nicholas J and Rock, Michael J and Asfour, Fadi and Howenstine, Michelle and Gaffin, Jonathan M and Lai, HuiChuan J},
  title = {Impact of acid blocker therapy on growth, gut microbiome, and lung disease in young children with cystic fibrosis},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2024},
  doi = {10.1002/jpn3.12389}
}
Kostenlos starten →